alanine has been researched along with Hypertension in 54 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012) |
| "Association of polymorphic markers G7831A of ACE gene, Lys198Asn of endothelin-1 (EDN1) gene, and 4a/4b of NOS3 gene with characteristics of structure and function of the left ventricle was studied in 70 (31 men and 39 women) natives of Yakutia with hypertension." | 7.73 | [Angiotensin converting enzyme, NO-synthase, and endothelin-1 genes and left ventricular hypertrophy in natives of Yakutia with hypertensive disease]. ( Antipina, VV; Makarova, ER; Minushkina, LO; Nosikov, VV; Petrova, IR; Romanova, TA; Sidorenko, BA; Zateĭshikov, DA, 2005) |
| "Previous studies by our group demonstrated a striking relationship among arginine, nitric oxide production, and salt-sensitive hypertension in the Dahl/Rapp rat." | 7.70 | Studies of arginine metabolism and salt sensitivity in the Dahl/Rapp rat models of hypertension. ( Chen, PY; Hamm, DA; Sanders, PW; Wood, PA, 1998) |
| "The possibility has been explored of using a specific angiotensin ii antagonist, saralasin (P-113, 1-sar-8-ala-angiotensin ii) to recognize patients whose hypertension depends upon excessive angiotensin ii activity." | 7.65 | Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. ( Anderson, GH; Dalakos, TG; Freiberg, JM; Streeten, DH, 1975) |
| "Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012) |
| " These drugs, such as omapatrilat, sampatrilat, fasidotrilat, by combined inhibition of ACE and degradation of natriuretic peptides and in turn by inhibiting the Renin - Angiotensin - Aldosterone system and potentiating the Natriuretic Peptide system and Kinin system should decrease the mortality rate in the group of patients with hypertension being not adequately controlled with ACE inhibitors." | 4.85 | The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment. ( Juszczak, K; Machowska, A; Novak, P; Thor, P, 2009) |
| "Association of polymorphic markers G7831A of ACE gene, Lys198Asn of endothelin-1 (EDN1) gene, and 4a/4b of NOS3 gene with characteristics of structure and function of the left ventricle was studied in 70 (31 men and 39 women) natives of Yakutia with hypertension." | 3.73 | [Angiotensin converting enzyme, NO-synthase, and endothelin-1 genes and left ventricular hypertrophy in natives of Yakutia with hypertensive disease]. ( Antipina, VV; Makarova, ER; Minushkina, LO; Nosikov, VV; Petrova, IR; Romanova, TA; Sidorenko, BA; Zateĭshikov, DA, 2005) |
| "Previous studies by our group demonstrated a striking relationship among arginine, nitric oxide production, and salt-sensitive hypertension in the Dahl/Rapp rat." | 3.70 | Studies of arginine metabolism and salt sensitivity in the Dahl/Rapp rat models of hypertension. ( Chen, PY; Hamm, DA; Sanders, PW; Wood, PA, 1998) |
| "The possibility has been explored of using a specific angiotensin ii antagonist, saralasin (P-113, 1-sar-8-ala-angiotensin ii) to recognize patients whose hypertension depends upon excessive angiotensin ii activity." | 3.65 | Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. ( Anderson, GH; Dalakos, TG; Freiberg, JM; Streeten, DH, 1975) |
| "Salt-induced hypertension is one of the major issues worldwide and one of the main factors involved in heart and kidney failure." | 1.72 | Benincasa hispida extracts positively regulated high salt-induced hypertension in Dahl salt-sensitive rats: Impact on biochemical profile and metabolic patterns. ( Ahmad, H; Ahmad, N; Chen, M; Du, J; Jin, Y; Khan, A; Li, X; Ouyang, Y; Tian, Z; Yang, P; Yang, Z; Zeng, L; Zhao, X; Zheng, X, 2022) |
| "Hypertension is a major risk factor for cardiovascular disease." | 1.36 | Assessment of a polymorphism of SDK1 with hypertension in Japanese Individuals. ( Aoyagi, Y; Kato, K; Metoki, N; Nozawa, Y; Oguri, M; Satoh, K; Watanabe, S; Yamada, Y; Yokoi, K; Yoshida, H; Yoshida, T, 2010) |
| "Hypertension was defined as known or newly diagnosed hypertension according to current national guidelines." | 1.33 | Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. ( Berthold, HK; Faust, M; Giannakidou, E; Gouni-Berthold, I; Kotzka, J; Krone, W; Müller-Wieland, D, 2005) |
| "Essential hypertension is considered to be a typical complex disease with multifactorial etiology, which leads to inconsistent findings in genetic studies." | 1.33 | Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. ( Chen, R; Chen, S; Ge, D; Gu, D; Huang, J; Li, B; Qiang, B; Su, S, 2006) |
| "Amlodipine did not affect cardiac hypertrophy." | 1.32 | Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. ( Allen, TJ; Burrell, LM; Cao, Z; Cooper, ME; Davis, BJ; Lassila, M, 2003) |
| "Because insulin sensitivity is likely to be determined by polygenic factors, we also investigated beta3 adrenergic receptor Trp64Arg polymorphism as a possible determinant of insulin resistance." | 1.31 | PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients. ( Ishibashi, K; Kageyama, S; Mimura, A; Nemoto, M; Sakurai, T; Sasaki, T; Tajima, N; Yamamoto, J; Yokota, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (27.78) | 18.7374 |
| 1990's | 10 (18.52) | 18.2507 |
| 2000's | 15 (27.78) | 29.6817 |
| 2010's | 6 (11.11) | 24.3611 |
| 2020's | 8 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Ayodele, O | 1 |
| Ren, K | 1 |
| Zhao, J | 1 |
| Signorovitch, J | 1 |
| Jonsson Funk, M | 1 |
| Zhu, J | 1 |
| Bao, Y | 1 |
| Gondek, K | 1 |
| Keenan, H | 1 |
| Ng, WY | 1 |
| Atan, R | 1 |
| Mohd Yunos, N | 1 |
| Bin Md Kamal, AH | 1 |
| Roslan, MH | 1 |
| Quah, KY | 1 |
| Teh, KX | 1 |
| Zaid, M | 1 |
| Kassim, M | 1 |
| Mariapun, J | 1 |
| Ngim, CF | 1 |
| Dhanoa, A | 1 |
| Yeo, TW | 1 |
| Ahmad, H | 1 |
| Zhao, X | 1 |
| Ahmad, N | 1 |
| Khan, A | 1 |
| Jin, Y | 1 |
| Du, J | 1 |
| Zheng, X | 1 |
| Zeng, L | 1 |
| Ouyang, Y | 1 |
| Yang, P | 1 |
| Chen, M | 1 |
| Li, X | 1 |
| Yang, Z | 1 |
| Tian, Z | 1 |
| Sise, ME | 1 |
| Baggett, MV | 1 |
| Shepard, JO | 1 |
| Stevens, JS | 1 |
| Rhee, EP | 1 |
| Ferguson, J | 1 |
| Rosser, JI | 1 |
| Quintero, O | 1 |
| Scott, J | 1 |
| Subramanian, A | 1 |
| Gumma, M | 1 |
| Rogers, A | 1 |
| Kappagoda, S | 1 |
| Wang, Y | 1 |
| Foo, R | 1 |
| Thum, T | 1 |
| Ambrosino, I | 1 |
| Barbagelata, E | 1 |
| Corbi, G | 1 |
| Ciarambino, T | 1 |
| Politi, C | 1 |
| Moretti, AM | 1 |
| Haji Aghajani, M | 1 |
| Moradi, O | 1 |
| Amini, H | 1 |
| Azhdari Tehrani, H | 1 |
| Pourheidar, E | 1 |
| Rabiei, MM | 1 |
| Sistanizad, M | 1 |
| Chekmeneva, E | 1 |
| Dos Santos Correia, G | 1 |
| Gómez-Romero, M | 1 |
| Stamler, J | 2 |
| Chan, Q | 2 |
| Elliott, P | 2 |
| Nicholson, JK | 1 |
| Holmes, E | 1 |
| Brown, IJ | 1 |
| Daviglus, ML | 1 |
| Miura, K | 1 |
| Okuda, N | 1 |
| Ueshima, H | 1 |
| Zhao, L | 1 |
| Regieli, JJ | 1 |
| Jukema, JW | 1 |
| Doevendans, PA | 1 |
| Zwinderman, AH | 1 |
| van der Graaf, Y | 1 |
| Kastelein, JJ | 1 |
| Grobbee, DE | 1 |
| De Cosmo, S | 1 |
| Motterlini, N | 1 |
| Prudente, S | 1 |
| Pellegrini, F | 1 |
| Trevisan, R | 1 |
| Bossi, A | 1 |
| Remuzzi, G | 1 |
| Trischitta, V | 1 |
| Ruggenenti, P | 1 |
| Oguri, M | 1 |
| Kato, K | 1 |
| Yokoi, K | 1 |
| Yoshida, T | 1 |
| Watanabe, S | 1 |
| Metoki, N | 1 |
| Yoshida, H | 1 |
| Satoh, K | 1 |
| Aoyagi, Y | 1 |
| Nozawa, Y | 1 |
| Yamada, Y | 1 |
| Peng, Y | 1 |
| Luo, XJ | 1 |
| Chen, XP | 1 |
| Li, LX | 1 |
| Wan, LY | 1 |
| He, S | 1 |
| Chen, XN | 1 |
| Wu, K | 1 |
| Machowska, A | 1 |
| Juszczak, K | 1 |
| Novak, P | 1 |
| Thor, P | 1 |
| Kardara, D | 1 |
| Tousoulis, D | 1 |
| Antoniades, C | 1 |
| Koumallos, N | 1 |
| Xaplanteris, P | 1 |
| Kyvelou, SM | 1 |
| Papageorgiou, N | 1 |
| Vasiliadou, C | 1 |
| Vlachopoulos, C | 1 |
| Stefanadis, C | 1 |
| Finn, RS | 1 |
| Kang, YK | 1 |
| Mulcahy, M | 1 |
| Polite, BN | 1 |
| Lim, HY | 1 |
| Walters, I | 1 |
| Baudelet, C | 1 |
| Manekas, D | 1 |
| Park, JW | 1 |
| Lassila, M | 1 |
| Davis, BJ | 1 |
| Allen, TJ | 1 |
| Burrell, LM | 1 |
| Cooper, ME | 1 |
| Cao, Z | 1 |
| MUIRHEAD, EE | 1 |
| JONES, F | 1 |
| STIRMAN, JA | 1 |
| Beige, J | 1 |
| Bellmann, A | 1 |
| Sharma, AM | 1 |
| Gessner, R | 1 |
| Gouni-Berthold, I | 1 |
| Giannakidou, E | 1 |
| Müller-Wieland, D | 1 |
| Faust, M | 1 |
| Kotzka, J | 1 |
| Berthold, HK | 1 |
| Krone, W | 1 |
| Minushkina, LO | 1 |
| Petrova, IR | 1 |
| Romanova, TA | 1 |
| Antipina, VV | 1 |
| Makarova, ER | 1 |
| Zateĭshikov, DA | 1 |
| Nosikov, VV | 1 |
| Sidorenko, BA | 1 |
| Stefański, A | 1 |
| Majkowska, L | 1 |
| Ciechanowicz, A | 1 |
| Frankow, M | 1 |
| Safranow, K | 1 |
| Parczewski, M | 1 |
| Moleda, P | 1 |
| Pilarska, K | 1 |
| Gu, D | 1 |
| Su, S | 1 |
| Ge, D | 1 |
| Chen, S | 1 |
| Huang, J | 1 |
| Li, B | 1 |
| Chen, R | 1 |
| Qiang, B | 1 |
| Zhang, A | 1 |
| Zhang, M | 1 |
| Zhang, J | 1 |
| Yu, Y | 1 |
| Xie, J | 1 |
| Gacka, M | 1 |
| Dobosz, T | 1 |
| Szymaniec, S | 1 |
| Bednarska-Chabowska, D | 1 |
| Adamiec, R | 1 |
| Canani, LH | 1 |
| Leie, MA | 1 |
| Machado, WE | 1 |
| Capp, C | 1 |
| Maia, AL | 1 |
| Lilequist, R | 1 |
| Paasonen, MK | 1 |
| Solatunturi, E | 1 |
| Seymour, AA | 3 |
| Abboa-Offei, BE | 1 |
| Smith, PL | 1 |
| Mathers, PD | 1 |
| Asaad, MM | 3 |
| Rogers, WL | 2 |
| Fournié-Zaluski, MC | 1 |
| Gonzalez, W | 1 |
| Turcaud, S | 1 |
| Pham, I | 1 |
| Roques, BP | 1 |
| Michel, JB | 1 |
| Dorella, M | 1 |
| Giusto, M | 1 |
| Da Tos, V | 1 |
| Campagnolo, M | 1 |
| Palatini, P | 1 |
| Rossi, G | 1 |
| Ceolotto, G | 1 |
| Felice, M | 1 |
| Semplicini, A | 1 |
| Del Prato, S | 1 |
| Yamaguchi, M | 1 |
| Takada, M | 1 |
| Nozaki, O | 1 |
| Ito, M | 1 |
| Furukawa, Y | 1 |
| Wegner, M | 1 |
| Hirth-Dietrich, C | 1 |
| Knorr, A | 1 |
| Dressel, J | 1 |
| Ganten, D | 1 |
| Stasch, JP | 1 |
| Wood, PA | 1 |
| Hamm, DA | 1 |
| Chen, PY | 1 |
| Sanders, PW | 1 |
| Ashworth-Preece, MA | 1 |
| Chen, F | 1 |
| Jarrott, B | 1 |
| Lawrence, AJ | 1 |
| Laurent, S | 1 |
| Boutouyrie, P | 1 |
| Azizi, M | 1 |
| Marie, C | 1 |
| Gros, C | 1 |
| Schwartz, JC | 1 |
| Lecomte, JM | 1 |
| Bralet, J | 1 |
| Chuang, LM | 1 |
| Hsiung, CA | 1 |
| Chen, YD | 1 |
| Ho, LT | 1 |
| Sheu, WH | 1 |
| Pei, D | 1 |
| Nakatsuka, CH | 1 |
| Cox, D | 1 |
| Pratt, RE | 1 |
| Lei, HH | 1 |
| Tai, TY | 1 |
| Yamamoto, J | 1 |
| Kageyama, S | 1 |
| Nemoto, M | 1 |
| Sasaki, T | 1 |
| Sakurai, T | 1 |
| Ishibashi, K | 1 |
| Mimura, A | 1 |
| Yokota, K | 1 |
| Tajima, N | 1 |
| Streeten, DH | 1 |
| Anderson, GH | 1 |
| Freiberg, JM | 1 |
| Dalakos, TG | 1 |
| Laragh, JH | 1 |
| Pettinger, WA | 1 |
| Keeton, K | 1 |
| Tanaka, K | 1 |
| Norman, JA | 2 |
| Fennell, SA | 2 |
| Little, DK | 2 |
| Kratunis, VJ | 2 |
| Abboa-Offei, B | 1 |
| Delaney, NG | 1 |
| Hunt, JT | 1 |
| Di Donato, G | 1 |
| Peters, AM | 1 |
| George, P | 1 |
| Brown, J | 1 |
| Lavender, JP | 1 |
| Peden, NR | 1 |
| Dow, RJ | 1 |
| Isles, TE | 1 |
| Martin, BT | 1 |
| Yee, KF | 1 |
| Buchanan, KD | 1 |
| Keenan, RE | 1 |
| Chobanian, AV | 1 |
| Stenbaek, O | 1 |
| Chazov, EI | 1 |
| Smirnov, VN | 1 |
| Mazaev, AV | 1 |
| Asafov, GB | 1 |
| Degtiar', VG | 1 |
| Niemeyer, G | 1 |
| Marquardt, JL | 1 |
| Savenko, SN | 1 |
| Vladkovskiĭ, IK | 1 |
| Maidanik, FE | 1 |
| Lindblad, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00005270] | 0 participants | Observational | 1995-09-30 | Completed | |||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
2 reviews available for alanine and Hypertension
| Article | Year |
|---|---|
The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial Natriuretic Facto | 2009 |
Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Topics: Alanine; Animals; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Heart Failure; Hemodynamics | 1995 |
5 trials available for alanine and Hypertension
| Article | Year |
|---|---|
Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.
Topics: Adult; Aged; Alanine; Albuminuria; Alleles; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure | 2009 |
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alanine; alpha-Fetoproteins; Appetite; Carcino | 2012 |
Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.
Topics: Adult; Aged; Alanine; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Cross-Over Studies; D | 1996 |
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Humans; Hypertension; Ne | 2000 |
The effect of chronic treatment with a non-selective beta-adrenoceptor antagonist on the enteroinsular axis and intermediary metabolites.
Topics: 3-Hydroxybutyric Acid; Adult; Aged; Alanine; Antihypertensive Agents; Blood Glucose; Clinical Trials | 1985 |
47 other studies available for alanine and Hypertension
| Article | Year |
|---|---|
Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-Inflammatory Agen | 2021 |
A double whammy: The association between comorbidities and severe dengue among adult patients-A matched case-control study.
Topics: Adult; Alanine; Albumins; Aspartate Aminotransferases; Case-Control Studies; Creatine Kinase; Creati | 2022 |
Benincasa hispida extracts positively regulated high salt-induced hypertension in Dahl salt-sensitive rats: Impact on biochemical profile and metabolic patterns.
Topics: Alanine; Amino Acids; Animals; Antihypertensive Agents; Antioxidants; Aspartic Acid; Cucurbitaceae; | 2022 |
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Amides; Anti-Inflammatory Agents; Antic | 2020 |
Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020.
Topics: Adenosine Monophosphate; Aged; Aged, 80 and over; Alanine; Asthma; Azithromycin; Betacoronavirus; Ca | 2020 |
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betaco | 2020 |
Gender differences in treatment of Coronavirus Disease-2019.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascul | 2020 |
Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Aspirin; Blood Platelets; Coronary | 2021 |
Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry and Direct Infusion-High-Resolution Mass Spectrometry for Combined Exploratory and Targeted Metabolic Profiling of Human Urine.
Topics: Adult; Alanine; Chromatography, High Pressure Liquid; Creatine; Creatinine; Female; Humans; Hyperten | 2018 |
Dietary glycine and blood pressure: the International Study on Macro/Micronutrients and Blood Pressure.
Topics: Adult; Alanine; Blood Pressure; Blood Pressure Determination; China; Cross-Sectional Studies; Diet; | 2013 |
PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients.
Topics: Alanine; Amino Acid Substitution; Blood Pressure; Coronary Disease; Genetic Variation; Genotype; Hum | 2009 |
Assessment of a polymorphism of SDK1 with hypertension in Japanese Individuals.
Topics: Aged; Alanine; Asian People; Cell Adhesion Molecules; Cysteine; Female; Genetic Predisposition to Di | 2010 |
[Association of PPARgamma2 Pro12Ala polymorphism and cognitive dysfunction in hypertension patients].
Topics: Aged; Alanine; Alleles; Cognition Disorders; Female; Gene Frequency; Humans; Hypertension; Male; Mid | 2010 |
Effects of the Ala379Val polymorphism of lipoprotein-associated phospholipase A2 on thrombosis and inflammation in hypertensive patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alanine; Fibrinogen; Gene Frequency; Genotype; Heter | 2011 |
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Topics: Alanine; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ani | 2003 |
Potentiation of renoprival hypertension by alanine, pyruvate and lactate.
Topics: Alanine; Humans; Hypertension; Hypertension, Renal; Lactates; Lactic Acid; Nephrectomy; Pyruvates; P | 1957 |
Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension.
Topics: Adult; Aged; Alanine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Gene Frequency; | 2004 |
Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Analysis of Variance; Blood Pressure; Chi-Square Distributi | 2005 |
[Angiotensin converting enzyme, NO-synthase, and endothelin-1 genes and left ventricular hypertrophy in natives of Yakutia with hypertensive disease].
Topics: Adult; Alanine; Asparagine; Blood Flow Velocity; Endothelin-1; Female; Gene Frequency; Genotype; Gly | 2005 |
Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes.
Topics: Alanine; Alleles; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypert | 2006 |
Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese.
Topics: Alanine; Asian People; Case-Control Studies; Cytochrome P-450 CYP11B2; Epistasis, Genetic; Female; G | 2006 |
The influence of the Pro12Ala mutation of PPARgamma2 receptor gene on beta-cells restoration and insulin resistance in type 2 diabetes with hypertension.
Topics: Alanine; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Hypertension; Insulin Resista | 2005 |
[Influence of polymorphism pro12Ala of PPARgamma gene on endothelium destruction in patients with diabetes mellitus t. 2].
Topics: Adult; Aged; Alanine; Amino Acid Substitution; Blood Pressure; Body Mass Index; Diabetes Mellitus, T | 2005 |
Type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients.
Topics: Alanine; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypertension; Insulin Resistance; Iodi | 2007 |
beta-Alanine and alpha-L-alanine inhibit the exploratory activity of spontaneously hypertensive rats.
Topics: Alanine; Animals; beta-Alanine; Blood Platelets; Brain; Exploratory Behavior; Heart; Hypertension; L | 1982 |
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
Topics: Administration, Oral; Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Di | 1994 |
Preparation of corn peptide from corn gluten meal and its administration effect on alcohol metabolism in stroke-prone spontaneously hypertensive rats.
Topics: Acetaldehyde; Alanine; Amino Acids; Animals; Bacillus; Cerebrovascular Disorders; Chromatography, Ge | 1996 |
Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Blood Pre | 1996 |
Studies of arginine metabolism and salt sensitivity in the Dahl/Rapp rat models of hypertension.
Topics: Alanine; Animals; Arginine; Argininosuccinate Synthase; Blood Pressure; Body Weight; Citrulline; Dis | 1998 |
Visualisation of AMPA binding sites in the brain stem of normotensive and hypertensive rats.
Topics: Alanine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Binding Sites; Brain Ste | 1999 |
Fasidotril. Aladotril, alatriopril, BP 1137.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Drugs, Investigational; Endopeptid | 1999 |
Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance.
Topics: Adult; Age Factors; Aged; Alanine; Alleles; Blood Glucose; China; Family Health; Female; Genotype; G | 2001 |
Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance.
Topics: Adult; Age Factors; Aged; Alanine; Alleles; Blood Glucose; China; Family Health; Female; Genotype; G | 2001 |
Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance.
Topics: Adult; Age Factors; Aged; Alanine; Alleles; Blood Glucose; China; Family Health; Female; Genotype; G | 2001 |
Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance.
Topics: Adult; Age Factors; Aged; Alanine; Alleles; Blood Glucose; China; Family Health; Female; Genotype; G | 2001 |
PPARgamma2 pro12Ala polymorphism and insulin resistance in Japanese hypertensive patients.
Topics: Adult; Alanine; Alleles; Amino Acid Substitution; Arginine; Asian People; Gene Frequency; Genotype; | 2002 |
Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;.
Topics: Adult; Aged; Alanine; Angiotensin II; Blood Pressure; Furosemide; Humans; Hypertension; Hypertension | 1975 |
Editorial: Angiotensin blockade: new pharmacologic tools for understanding and treating hypertension.
Topics: Alanine; Angiotensin II; Diuretics; Humans; Hypertension; Hypertension, Renal; Propranolol; Sarcosin | 1975 |
Letter: Use and toxicity of nitroprusside.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Cyanides; Ferricyanides; Humans; Hyperten | 1975 |
Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients.
Topics: Adult; Alanine; Angiotensin II; Animals; Antibody Specificity; Antigen-Antibody Complex; Dose-Respon | 1975 |
Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase.
Topics: Alanine; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Cyclic GMP; Desoxycorticostero | 1991 |
Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.
Topics: Alanine; Animals; Atrial Natriuretic Factor; Blood Pressure; Desoxycorticosterone; Hypertension; Mal | 1991 |
Filtration fraction.noninvasive measurement with Tc-99m DTPA and changes induced by angiotensin-converting enzyme inhibition in hypertension.
Topics: Adult; Aged; Alanine; beta-Alanine; Captopril; Female; Glomerular Filtration Rate; Humans; Hypertens | 1989 |
Letter: Test for role of angiotensin in hypertension.
Topics: Alanine; Angiotensin II; Humans; Hypertension; Sarcosine | 1974 |
Editorial: Angiotensin inhibition.
Topics: Alanine; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Press | 1974 |
[Angiotensin blockade and hypertension].
Topics: Alanine; Angiotensin II; Animals; Blood Pressure; Depression, Chemical; Humans; Hypertension; Sarcos | 1974 |
[Coronary arterio-venous difference in the concentration of various products of nitrogen metabolism in man].
Topics: Adult; Alanine; Ammonia; Aorta; Arteriosclerosis; Coronary Disease; Coronary Vessels; Glutamates; Gl | 1972 |
Retinal function in an unique syndrome of optic atrophy, juvenile diabetes mellitus, diabetes insipidus, neurosensory hearing loss, autonomic dysfunction, and hyperalanineuria.
Topics: Adaptation, Ocular; Adult; Alanine; Amino Acid Metabolism, Inborn Errors; Diabetes Insipidus; Diabet | 1972 |
[The serum amino acid spectrum of hypertensive patients with cerebral circulatory disorders].
Topics: Adult; Aged; Alanine; Amino Acids; Arginine; Aspartic Acid; Cerebrovascular Disorders; Female; Human | 1971 |
The venous plasma free amino acid levels during the first hours of life. I. After normal and short gestation and gestation complicated by hypertension, with special reference to the "small for dates" syndrome.
Topics: Alanine; Amino Acids; Arginine; Birth Weight; Blood Glucose; Body Height; Chromatography, Ion Exchan | 1970 |